Invivyd, Inc. (NasdaqGM: IVVD)
Health Care · Biotechnology · US
$0.94
+30.21% today · +24.1% 1Y
Invivyd, Inc. (NasdaqGM: IVVD) operates in the Biotechnology industry within the Health Care sector. The company is valued at $212.49M and employs 122 people.
Over the last twelve months the share price has gained 24.1%, trading between 0.48 and 3.07.
Tweenvest scores Invivyd, Inc. across four factors: quality 28/100, value 62/100. Its strongest factor is value.
IVVD price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $212.49M
- Revenue (TTM)
- $58.37M
- P/E
- —
- EPS
- -0.40
- Dividend yield
- —
- Beta (5Y)
- 0.71
- 52-week high
- $3.07
- 52-week low
- $0.48
- Avg volume (3M)
- —
- Shares outstanding
- 294.76M
- Employees
- 122
- Next earnings
- —
About Invivyd, Inc.
Adagio Therapeutics, Inc., a biopharmaceutical firm in its clinical development phase, operates within the United States, specializing in the discovery, progression, and marketing of antibody-derived solutions for infectious diseases. The company's leading drug candidate, ADG20 (adintrevimab), is a neutralizing antibody currently undergoing Phase 3 clinical investigation for both the management and prevention of coronavirus disease. Adagio Therapeutics maintains collaborative agreements with Adimab, LLC to facilitate the identification and enhancement of its exclusive antibodies. Furthermore, it partners with the Scripps Research Institute to conduct studies aimed at uncovering potential vaccine solutions for the prophylaxis, detection, or therapy of influenza or beta coronaviruses. Incorporated in 2020, the company's base of operations is in Waltham, Massachusetts.
- ISIN
- US00534A1025
- Founded
- 2020
- Listed since
- Aug 6, 2021
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $265.80 | +0.00% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $444.99 | +0.62% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.10 | -0.45% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $552.50 | -0.06% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $832.63 | -0.11% |
| argenx SEENXTBR: ARGX | $64.17B | €903.40 | +2.75% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $154.84 | -2.51% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.